NMPA Approval Trends ADCs: Novel Lung Cancer Therapies in China 2025
Discover the latest NMPA approval trends for antibody-drug conjugates (ADCs) targeting lung cancer in China, focusing on innovative therapies expected by 2025.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: April 29, 2026
Key Takeaways
- NMPA milestone: China's National Medical Products Administration approved 120 new drugs in 2025, including three novel antibody-drug conjugates (ADCs) in oncology. This reflects an acceleration in regulatory processes for innovative cancer therapies.
- Lung cancer focus: Two ADCs—trastuzumab rezetecan (HER2-targeted) and sacituzumab govitecan (TROP2-targeted)—received approval for non-small cell lung cancer (NSCLC), broadening targeted treatment options for a significant patient group.
- Domestic innovation driver: These approvals highlight China's advancing capabilities in ADC development, primarily from domestic innovators rather than multinational firms, altering the competitive dynamics in APAC oncology.
- Market acceleration: The 2025 NMPA ADC approvals emphasize China's focus on rapid pathways for novel oncology therapies, establishing the country as a critical center for drug development and regulatory innovation in the region.
In 2025, China's National Medical Products Administration (NMPA) approved 120 new drugs, including three novel antibody-drug conjugates (ADCs) targeting oncology. Among these, trastuzumab rezetecan and sacituzumab govitecan received approval for non-small cell lung cancer (NSCLC), significantly expanding treatment options in one of the world’s largest cancer markets. The approvals indicate China's evolving role in oncology and reflect the NMPA's commitment to expedite access to novel ADC therapies for patients.
Drug Overview
Trastuzumab rezetecan is a HER2-directed antibody-drug conjugate designed for patients with HER2-expressing non-small cell lung cancer. It merges a humanized anti-HER2 monoclonal antibody with a cytotoxic payload, allowing for targeted chemotherapy delivery to cancer cells expressing the HER2 receptor. Sacituzumab govitecan is a TROP2-directed ADC that targets trophoblast cell surface antigen 2 (TROP2), commonly expressed in NSCLC and other solid tumors. Both agents offer unique mechanisms within the ADC class, providing complementary options for HER2-positive and TROP2-positive NSCLC patients.
The NMPA's approval of these two ADCs in 2025 highlights the regulatory body's acknowledgment of ADCs as vital therapeutic options for lung cancer treatment. Compared to traditional chemotherapy, ADCs potentially provide better selectivity and less systemic toxicity through targeted delivery. However, specific clinical efficacy and safety profiles depend on each agent and patient population.
Clinical Insights
Specific clinical trial data—including trial names, phases, primary endpoints, efficacy metrics (overall response rate, progression-free survival, overall survival), and grade ≥3 adverse event profiles—were not disclosed in the available regulatory approval documentation. The NMPA's approval decisions for trastuzumab rezetecan and sacituzumab govitecan were based on clinical evidence from the manufacturers; however, detailed efficacy and safety data from pivotal trials have not been released in this analysis.
What to watch next: As these drugs enter the Chinese market and real-world data emerges, post-marketing surveillance reports and comparative effectiveness studies will be critical to understanding their clinical performance against existing NSCLC therapies and competing ADCs.
Regulatory Context
The NMPA approved trastuzumab rezetecan and sacituzumab govitecan as part of its 2025 drug approval group, highlighting the agency's commitment to expedited pathways for novel oncology therapies. The NMPA has increasingly implemented accelerated review mechanisms and adaptive pathways for drugs addressing unmet medical needs in cancer treatment, especially for targeted therapies with clear mechanistic rationale.
China's regulatory framework for ADC approvals has significantly progressed over the last five years, with the NMPA providing clearer guidelines on manufacturing standards, analytical characterization, and nonclinical safety assessments for ADC products. This regulatory evolution has enabled quicker review timelines compared to previous years, facilitating the approval of several novel ADCs within a single cycle. The 2025 approvals align with the NMPA's strategy to minimize the drug approval gap between China and other major markets (FDA, European Medicines Agency) and to enhance domestic innovation in advanced therapeutics.
Market Impact
Non-small cell lung cancer is one of the largest oncology markets in China, with hundreds of thousands of patients diagnosed each year. The approval of trastuzumab rezetecan and sacituzumab govitecan broadens the treatment landscape for patients with HER2-positive and TROP2-positive NSCLC, respectively, addressing previously underserved patient groups. These ADCs introduce new mechanisms of action that set them apart from existing targeted therapies (such as EGFR inhibitors and ALK inhibitors) and conventional chemotherapy regimens.
The competitive implications are significant: the introduction of these two novel ADCs intensifies competition among companies developing advanced oncology therapies. Domestic innovators have taken the lead in bringing these ADCs to market, showcasing China's growing research and development capabilities and manufacturing expertise in the ADC sector. This trend is likely to accelerate the development of additional ADC candidates targeting lung cancer and other malignancies in China.
Manufacturing scale and cost-sensitive adoption remain crucial factors for APAC markets. As ADC production capacity increases in China, economies of scale could improve, potentially lowering drug costs and enhancing patient access compared to imported ADCs. The regulatory framework established by the NMPA for these approvals could also speed up the entry of biosimilar ADCs in the coming years, further influencing the competitive landscape and pricing dynamics in the region.
Future Outlook
The NMPA's 2025 approvals of trastuzumab rezetecan and sacituzumab govitecan are likely to stimulate further ADC development in China's oncology sector. Additional ADC candidates targeting NSCLC and other tumor types are expected to appear in the pipelines of both domestic and international pharmaceutical companies, with potential NMPA submissions anticipated in 2026 and beyond. Expansion of approved indications—such as combination therapies with immunotherapy agents or applications to other cancer types—may arise as clinical data accumulate.
China's increasing investment in domestic research and development for oncology therapeutics suggests a rising proportion of ADC approvals driven by local innovators. This shift has strategic implications for multinational pharmaceutical companies operating in APAC, which may need to accelerate their own ADC development efforts or pursue partnerships with Chinese biotech firms to stay competitive. Manufacturing capabilities and biosimilar development will be key differentiators in the evolving APAC market, especially as cost-sensitive adoption models gain traction across the region.
Frequently Asked Questions
What is an antibody-drug conjugate (ADC), and how do trastuzumab rezetecan and sacituzumab govitecan differ?
Antibody-drug conjugates are therapeutic molecules that link a monoclonal antibody with a cytotoxic payload through a chemical linker. The antibody component targets specific antigens on cancer cells, allowing for selective delivery of the chemotherapy payload. Trastuzumab rezetecan targets HER2, a receptor often overexpressed in certain lung cancers, while sacituzumab govitecan targets TROP2, a tumor-associated antigen found on NSCLC and other solid tumors. These distinct targeting mechanisms enable treatment of different patient populations with HER2-positive or TROP2-positive disease.
Why is the NMPA approval of these ADCs significant for China's oncology market?
The 2025 NMPA approvals signify an important development in China's regulatory evolution and drug development capabilities. These approvals indicate that the NMPA is bringing novel oncology therapies to market in a timeline that competes with other major regulatory agencies. Moreover, the leading role of domestic innovators in these ADC approvals reflects China's growing expertise in advanced therapeutics manufacturing and clinical development, potentially reducing the historical lag in access to advanced cancer treatments.
How do these ADC approvals compare with regulatory trends in other APAC regions?
China's 2025 ADC approvals demonstrate accelerating regulatory momentum in the broader APAC region. The NMPA's approval of multiple novel ADCs in a single year aligns with similar initiatives by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) and the Therapeutic Goods Administration (TGA) in Australia aimed at expediting review of innovative oncology therapies. However, the high proportion of approvals driven by domestic Chinese innovators sets the NMPA's approach apart and highlights the region's growing self-sufficiency in drug development.
What are the implications for patient access and pricing in China?
The approval of trastuzumab rezetecan and sacituzumab govitecan is expected to enhance treatment options for NSCLC patients in China, particularly those with HER2-positive or TROP2-positive disease. As manufacturing capacity for these ADCs increases domestically, economies of scale should improve, potentially lowering costs and expanding patient access. The NMPA's regulatory framework may also accelerate the entry of biosimilar ADCs in future years, supporting cost-sensitive adoption models that align with APAC healthcare priorities.
What ADC candidates are expected to enter the NMPA pipeline in 2026 and beyond?
While specific pipeline timelines were not disclosed in the 2025 approval announcements, industry trends suggest that additional ADC candidates targeting NSCLC and other malignancies are in development at both domestic Chinese companies and international pharmaceutical firms. Potential areas of focus include combination therapies pairing ADCs with immune checkpoint inhibitors, expansion to other solid tumors, and development of next-generation ADCs with improved pharmacokinetic profiles or novel payloads. Regulatory submissions to the NMPA are anticipated in 2026 and subsequent years.
References
- National Medical Products Administration (NMPA). 2025 Drug Approval Summary: Oncology Antibody-Drug Conjugate Approvals. Regulatory announcement and approval documentation.
Asia-Pacific Editor
Dr. Yuki Tanaka is an oncologist specializing in Asian pharmaceutical markets and regulatory harmonization. Former PMDA reviewer with expertise in bridging studies and ethnic factors....
